

Table of Contents

1. Introduction	3
1.1. Alzheimer's disease	3
1.2. Statistics of AD	4
1.3. Pathophysiology of AD.....	5
1.3.1 Role of acetyl and butyrylcholines in AD.....	5
1.3.2 Role of amyloid beta (A β) and tau proteins.....	7
1.3.3 Role of metals in AD.....	9
1.3.4 Role of oxidative stress (OS) in AD	12
1.3.5 Role of β -secretase (BACE) in AD.....	14
1.3.6 Role of NLRP3 (NOD-like receptor family pyrin domain containing 3) Inflammasome in AD	15
1.4. Current drug targets for AD	16
1.4.1 Cholinesterases (ChEs)	16
1.4.2 NMDA receptor in AD.....	18
1.4.3 Monoclonal antibodies targeting Amyloid beta (A β) aggregates	19
2. Literature Review	23
2.1. Current therapies for AD.....	23
2.1.1 Cholinesterase inhibitors (ChEIs).....	23
2.1.2 Noncompetitive N-methyl-D-aspartate (NMDA) antagonists.....	24
2.2. Antioxidant therapy for AD	25
2.3. Metal (iron) chelators in a clinical trial for the treatment of AD	26
2.4. Monoclonal antibodies in AD treatment.....	28
2.5. Literature review related to urea and carbamate-based hybrids for the management of AD.....	29
2.6. Literature available based on urea-based scaffolds for the management of AD.....	30

2.7.	Literature reported based on the carbamate fragment (RIV scaffold)	35
3.	Objective, Rationale, and Plan of Work	53
3.1.	Objective and Rationale	54
3.2.	Plan of Work	60
4.	Results & Discussion.....	65
4.1.	Rationale behind the design of diphenylurea-amidine derivatives	65
4.2.	Chemistry and synthetic schemes involved in the first series of diphenylurea-amidine derivatives	68
4.3.	Biological evaluation of the first series of diphenylurea-amidine derivatives	71
4.3.1	SAR studies of synthesized molecules against <i>hAChE</i> , <i>eqBChE</i> , <i>hBChE</i>	71
4.3.2	Kinetic studies of <i>hAChE</i> and <i>eqBChE</i> inhibition	76
4.3.3	Quantification of propidium iodide displacement from the peripheral anionic site of <i>AChE</i>	77
4.3.4	Molecular docking and dynamic study of 3q and 6e	78
4.3.5	Molecular dynamics simulation.....	83
4.3.6	Antioxidant assay.....	86
4.3.7	Inhibition of <i>self-mediated</i> $A\beta_{1-42}$ aggregation.....	87
4.3.8	Molecular docking and simulation against amyloid beta	88
4.3.9	Tau protein aggregation inhibition.....	91
4.3.10	Evaluation of metal chelating and NO release property	92
4.3.11	Cell cytotoxicity assessment of 3q and 6e against PC12.....	94
4.3.12	Evaluation of the neuroprotective effect of 3q and 6e against H_2O_2 -induced cell death.....	95
4.3.13	Effect of neuroprotective drug 3q and 6e on apoptosis.	96
4.3.14	Evaluation of NLRP3 inflammasome inhibitory property.....	98
4.3.15	Evaluation of neuroprotection ability of 3q , 6e and RIV in AD drosophila model.....	104
4.3.16	<i>In-vitro</i> blood-brain barrier permeation assay	111

4.3.17	Acute toxicity and hepatotoxicity studies	112
4.3.18	Evaluation of <i>in-vivo</i> efficacy of 3q & 6e in scopolamine-induced AD mice model.....	113
4.3.19	Neurochemical Profiling and Antioxidant Property Assessment.....	114
4.3.20	Evaluating <i>in-vivo</i> efficacy of 3q and 6e in reversing scopolamine-induced cognitive deficits in the Morris water maze test.....	116
4.4.	Rationale behind the design of the second series of carbamate-based tryptamine derivative.....	122
4.5.	Chemistry and synthetic schemes involved in the second series of carbamate-based tryptamine derivatives.....	124
4.6.	Biological evaluation of the second series of compounds	126
4.6.1	Cholinesterase Inhibition Studies	126
4.6.2	Enzyme Kinetic studies of <i>hAChE</i> and <i>eqBChE</i> inhibition	128
4.6.3	Inhibition of the peripheral anionic site (PAS) of AChE	129
4.6.4	Molecular docking studies	130
4.6.5	Molecular dynamics studies.....	136
4.6.6	Evaluation of the antioxidant property	137
4.6.7	<i>In-vitro</i> cytotoxicity assessment.....	139
4.6.8	Evaluation of the metal chelation property	143
4.6.9	<i>In-vitro</i> blood-brain barrier permeation assay	144
4.6.10	Evaluation of A β_{1-42} aggregation inhibition property.....	145
4.6.11	Computational investigation of 15d and 15e interaction with A β_{1-42} fibrils	147
4.6.12	Evaluation of neuroprotection ability of 15d , 15e , and RIV in AD drosophila model.....	150
4.6.13	Acute toxicity study	156
4.6.14	Evaluation of <i>in-vivo</i> efficacy of 15d and 15e in reversing scopolamine-induced cognitive deficits through the Morris water maze test	156
4.6.15	ADMET Prediction.....	161
5.	Experimental work	165

5.1.	Chemistry	165
5.1.1	General procedure for synthesis of intermediates 2a-2w , 5a-5e , 8a-8e and 11a-11b	165
5.1.2	General procedure for synthesis of target compounds 3a-3w , 6a-6e , 9a-9e and 11a-11b	172
5.1.3	General procedure for the synthesis of intermediates 13a-13e	182
5.1.4	General procedure for synthesis of target compounds 14a-14e , 15a-15e and 16a	182
5.2.	Biological evaluation	189
5.2.1	Determination of IC ₅₀ values	189
5.2.2	Kinetic analysis and mode of AChE Inhibition	190
5.2.3	Enzyme kinetic investigation of lead compound 15e on AChE & BChE.....	190
5.2.4	Propidium iodide displacement assay	191
5.2.5	Molecular docking study of 3q and 6e against AChE and BChE.....	192
5.2.6	Molecular Dynamics	193
5.2.7	<i>In-silico</i> study of 15d and 15e against AChE and BChE.....	194
5.2.8	Covalent Docking of RIV, 15d and 15e against AChE and BChE	194
5.2.9	DPPH radical-scavenging potency	195
5.2.10	Amyloid- β aggregation studies	196
5.2.11	<i>In-silico</i> study of 3q , 6e , 15d and 15e against A β ₁₋₄₂ protofibrils	197
5.2.12	Molecular Dynamics Simulation Study	197
5.2.13	Tau protein aggregation inhibition studies.....	198
5.2.14	<i>In-vitro</i> metal chelating assay	199
5.2.15	Determining Nitrite Concentration	199
5.2.16	Cell Culture	200
5.2.17	Evaluation of NLRP3 inhibition property in a cell culture model.....	202
5.2.18	Fly husbandry and culture.....	204
5.2.19	PAMPA assay for in-vitro analysis of permeability	206
5.2.20	Animal studies	206

5.2.21 Behavioral studies by using the Morris water maze test.....	210
6. Summary and Conclusions	215
References.....	221
Appendix	235
List of Publications	249